In association with

CONTENTS

Special Issue | October 2018

personalised production

How will the rise of personalised medicine change manufacturing for drugmakers? 

the cost of CAR-T therapy

The high price behind one of the industry’s most advanced therapies

personalised drug combinations

How can AI help doctors rapidly identify optimal personalised drug combinations?

Precision meds: Microbiome vs Genetics 

Is the microbiome as important for precision medicine as genetics?

Manufacturing in china

Has a summer of manufacturing disasters for Chinese pharma impacted trust?

hurdles ahead for staph infection drug

ContraFect’s Staph infection drug may succeed in trials, but caveats remain

novel treatments for glioblastoma

Why are novel therapies for glioblastoma patients not gaining approvals?

CAR-T approval in europe

CAR-T has been approved in Europe, but with NICE divided, what happens next?

Master Data Management 2.0

Life sciences firms need to adapt how they approach data management

Transforming healthcare with digital tech

The industry is undergoing dramatic change as new tech brings disruption

02/23/2024 21:45:13
  • Home | Getting Personal
  • Scandinavian Health Ltd. Company Insight
  • Scandinavian Health Ltd.
  • In this issue
  • International Cannabis and Cannabinoid Institute (ICCI) Company Insight
  • International Cannabis and Cannabinoid Institute (ICCI)
  • Contents
  • Novo Nordisk
  • News
  • Phoenix
  • The Pharma Industry Briefing
  • Nelson Lab Company Insight
  • Nelson Labs
  • Manufacturing personalised meds: what needs to change?
  • Molnar Company Insight
  • Molnar
  • Selling cells: the economics of CAR-T therapy
  • Wilhelm Haselmeier GmbH & Co KG Company Insight
  • Wilhelm Haselmeier GmbH & Co. KG
  • Using AI to personalise drug combination therapy
  • NSF
  • Is the microbiome as important for precision medicine as genetics?
  • Nipro PharmaPackaging
  • A summer of manufacturing disasters for Chinese pharma
  • Capsugel
  • Endoca
  • ContraFect’s Staph infection drug may succeed in trial but caveats remain
  • Dow Europe GmbH Company Insight
  • Dow Europe GmbH
  • Why are novel therapies for glioblastoma patients not gaining approvals?
  • Lubrizol Life Sciences
  • QualiMetriX
  • CAR-T approved in Europe but NICE verdict is divided: what happens next?
  • Palleos healthcare GmbH
  • Daiichi Jitsugyo
  • Events
  • Nemera Company Insight
  • Erdmann Design Switzerland
  • Next issue
  • Nemera
  • Plastiape
  • General Electric Healthcare
09/28/2018 00:00:00